<DOC>
	<DOCNO>NCT01659047</DOCNO>
	<brief_summary>The purpose study evaluate effect GS-1101 onset , magnitude , duration tumor control</brief_summary>
	<brief_title>A Phase 2 , Single-Arm , Open-Label Study Evaluating Efficacy Safety Single Agent GS 1101 ( CAL 101 ) Therapy Previously Treated Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>This Phase 2 , multicenter , single-arm , control , clinical trial evaluate efficacy safety phosphatidylinositol 3-kinase delta ( PI3K-delta ) inhibitor GS-1101 ( CAL-101 ) therapy previously treat chronic lymphocytic leukemia . This clinical trial ( Study GS-US-312-0120 ) single-arm compliant subject GS US-312-0119 -Arm B experience progression CLL receive single-agent ofatumumab therapy potentially eligible receive single-agent , open-label GS 1101 therapy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>Participation Study GSUS3120119 Occurrence confirm progression CLL receive singleagent ofatumumab Study GS US 312 0119 . Permanent cessation Study GSUS3120119 ( singleagent ofatumumab ) intervene continue therapy ( include radiotherapy , chemotherapy , immunotherapy , investigational therapy ) treatment CLL . The time permanent cessation singleagent ofatumumab Study GSUS3120119 initiation GS 1101 Study GSUS3120120 12 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>CAL-101</keyword>
	<keyword>Ofatumumab</keyword>
</DOC>